Margaret M Hopeman1, Katherine E Cameron2, Maureen Prewitt2, Kurt Barnhart2, Jill P Ginsberg3, Mary D Sammel2, Clarisa R Gracia2. 1. Division of Reproductive Endocrinology and Infertility, Philadelphia, Pennsylvania. Electronic address: meg.hopeman@ivfmn.com. 2. Division of Reproductive Endocrinology and Infertility, Philadelphia, Pennsylvania. 3. Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: To develop and internally validate a clinical predictive tool to assess the likelihood that a young cancer patient will experience diminished ovarian reserve (DOR) after chemotherapy. DESIGN: Prospective cohort study. SETTING: University hospitals. PATIENT(S): Postpubertal adolescent and young adult women with a new diagnosis of cancer requiring chemotherapy. INTERVENTION: None. MAIN OUTCOME MEASURE(S): Diminished ovarian reserve after completion of and recovery from chemotherapy, defined as serum antimüllerian hormone (AMH) <1 ng/mL at 8-24 months after completion of chemotherapy. RESULT(S): A multivariable logistic regression model which includes age, cancer type, exposure to an alkylating agent, and baseline AMH value accurately predicts the diagnosis of DOR after chemotherapy with an area under the receiver operating characteristic curve of 0.89. CONCLUSION(S): Pretreatment information on age, cancer type, use of an alkylating agent, and baseline AMH levels make up a clinically useful predictive tool to identify which women are most at risk for DOR caused by chemotherapy.
OBJECTIVE: To develop and internally validate a clinical predictive tool to assess the likelihood that a young cancerpatient will experience diminished ovarian reserve (DOR) after chemotherapy. DESIGN: Prospective cohort study. SETTING: University hospitals. PATIENT(S): Postpubertal adolescent and young adult women with a new diagnosis of cancer requiring chemotherapy. INTERVENTION: None. MAIN OUTCOME MEASURE(S): Diminished ovarian reserve after completion of and recovery from chemotherapy, defined as serum antimüllerian hormone (AMH) <1 ng/mL at 8-24 months after completion of chemotherapy. RESULT(S): A multivariable logistic regression model which includes age, cancer type, exposure to an alkylating agent, and baseline AMH value accurately predicts the diagnosis of DOR after chemotherapy with an area under the receiver operating characteristic curve of 0.89. CONCLUSION(S): Pretreatment information on age, cancer type, use of an alkylating agent, and baseline AMH levels make up a clinically useful predictive tool to identify which women are most at risk for DOR caused by chemotherapy.
Authors: Lydia H Pecker; Sarah Hussain; Jaanvi Mahesh; Ravi Varadhan; Mindy S Christianson; Sophie Lanzkron Journal: Blood Date: 2022-02-17 Impact factor: 22.113
Authors: Esther H Chung; Stephanie L Lim; Evan Myers; Haley A Moss; Kelly S Acharya Journal: J Assist Reprod Genet Date: 2021-05-11 Impact factor: 3.357
Authors: Marie-Madeleine Dolmans; Isabelle Demeestere; Ellen Anckaert; Michel De Vos Journal: J Assist Reprod Genet Date: 2022-06-25 Impact factor: 3.357